EP Biocomposites Ltd
EP Biocomposites Ltd (EPBIO) last reported results for the quarter ended Mar 2026, with sales of ₹9.57 crore and net profit of ₹1.37 crore. The stock last traded at ₹92, a market capitalisation of ₹15.5 crore, on a P/E of 10.6. Over the past 52 weeks the stock has ranged between ₹75.5 and ₹150. Figures are as of 6 Oct 2026 and are not real time.
EP Biocomposites Ltd share price and key metrics
- Current price
- ₹92
- Market cap
- ₹15.5 cr
- Stock P/E
- 10.6
- Book value
- ₹71.7
- ROE
- 12.9%
- ROCE
- 16.3%
- Dividend yield
- 0.00%
- 52w high / low
- 150/75.5
Metrics as of 6 Oct 2026. Not real time.
Track EP Biocomposites Ltd
Cruxal reads every EP Biocomposites Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
EP Biocomposites Ltd growth and returns
- 10 Years
- %
- 5 Years
- 36%
- 3 Years
- 24%
- TTM
- 14%
- 10 Years
- %
- 5 Years
- 32%
- 3 Years
- 36%
- TTM
- 42%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -22%
- 1 Year
- -28%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 12%
- Last Year
- 13%
EP Biocomposites Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹9.57 cr, up 25.9% from ₹7.6 cr a year earlier. Net profit was ₹1.37 cr, up 65.1% year on year.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.45 | 3.68 | 4.4 | 7.04 | 4.4 | 7.6 | 4.07 | 9.57 |
| Expenses | 2.92 | 3.26 | 4.14 | 5.9 | 3.91 | 6.31 | 3.82 | 7.58 |
| Operating profit | 0.53 | 0.42 | 0.26 | 1.14 | 0.49 | 1.29 | 0.25 | 1.99 |
| OPM % | 15.36% | 11.41% | 5.91% | 16.19% | 11.14% | 16.97% | 6.14% | 20.79% |
| Other income | 0.03 | 0.13 | 0.09 | 0.21 | 0.05 | 0.06 | 0.07 | 0.07 |
| Interest | 0.15 | 0.05 | 0.01 | 0.02 | 0.17 | 0.19 | 0.15 | 0.19 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 |
| Profit before tax | 0.36 | 0.45 | 0.29 | 1.28 | 0.32 | 1.1 | 0.12 | 1.82 |
| Tax % | 25.00% | 33.33% | 27.59% | 27.34% | 34.38% | 25.45% | 33.33% | 24.73% |
| Net profit | 0.27 | 0.3 | 0.22 | 0.93 | 0.21 | 0.83 | 0.09 | 1.37 |
| EPS (₹) | 1.61 | 1.78 | 1.31 | 5.53 | 1.25 | 4.94 | 0.54 | 8.15 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
EP Biocomposites Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 2.95 | 8.06 | 7.12 | 11.43 | 12.01 | 13.64 |
| Operating profit | 0.46 | 1.4 | 0.97 | 1.41 | 1.78 | 2.24 |
| OPM % | 15.59% | 17.37% | 13.62% | 12.34% | 14.82% | 16.42% |
| Net profit | 0.36 | 0.81 | 0.58 | 1.15 | 1.03 | 1.46 |
| EPS (₹) | 72.00 | 6.88 | 3.45 | 6.84 | 6.13 | 8.68 |
TTM is the trailing twelve months to the most recent quarter.
EP Biocomposites Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0.05 | 0.05 | 1.18 | 1.68 | 1.68 | 1.68 | 1.68 |
| Reserves | -0.02 | 0.34 | 0.82 | 6.73 | 7.88 | 8.91 | 10.37 |
| Borrowings | 0.00 | 0.00 | 4.11 | 1.28 | 1.80 | 2.98 | 2.39 |
| Other liabilities | 0.52 | 0.94 | 3.16 | 2.03 | 3.72 | 3.06 | 4.30 |
| Total liabilities | 0.55 | 1.33 | 9.27 | 11.72 | 15.08 | 16.63 | 18.74 |
| Fixed assets | 0.00 | 0.00 | 0.41 | 0.33 | 0.33 | 0.23 | 0.24 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.14 | 0.62 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 0.55 | 1.33 | 8.86 | 11.39 | 14.61 | 16.26 | 17.88 |
| Total assets | 0.55 | 1.33 | 9.27 | 11.72 | 15.08 | 16.63 | 18.74 |
As reported by the company. Total assets equal total liabilities by construction.
EP Biocomposites Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 0.12 | 0.03 | -4.28 | -0.79 | -1.24 | -0.49 | 1.99 |
| Cash from investing | 0.00 | 0.00 | -0.47 | 0.02 | -0.16 | 0.02 | -0.53 |
| Cash from financing | 0.00 | 0.00 | 4.76 | 2.81 | 0.49 | 0.82 | -0.92 |
| Net cash flow | 0.12 | 0.03 | 0.01 | 2.04 | -0.92 | 0.35 | 0.54 |
| Free cash flow | 0.12 | 0.03 | -4.75 | -0.81 | -1.48 | -0.50 | 1.41 |
| CFO / operating profit | 300% | 9% | -294% | -44% | -59% | -1% | 105% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
EP Biocomposites Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 219.05% | 41.54% | 13.16% | 15.30% | 14.28% | 16.28% |
| Debtor days | 192.11 | 80.42 | 321.53 | 300.41 | 287.40 | 330.05 | 316.83 |
| Inventory days | 83.65 | 90.25 | 86.83 | 90.58 | 50.13 | 66.66 | 56.54 |
| Days payable | 349.79 | 128.35 | 161.90 | 104.79 | 143.08 | 97.87 | 113.51 |
| Cash conversion cycle | -74.04 | 42.32 | 246.47 | 286.20 | 194.45 | 298.85 | 259.87 |
| Working capital days | -57.63 | 25.98 | 156.69 | 255.81 | 217.47 | 270.79 | 237.36 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
EP Biocomposites Ltd shareholding pattern
Promoters held 70.08% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.08% | 70.08% | 70.08% | 70.08% | 70.05% | 70.08% | 70.08% | 70.08% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 29.92% | 29.92% | 29.92% | 29.92% | 29.95% | 29.92% | 29.92% | 29.91% |
| No. of shareholders | 365 | 365 | 382 | 374 | 361 | 356 | 353 | 337 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
EP Biocomposites Ltd corporate filings
- EP Biocomposites Limited's AGM Voting Results Show Near-Complete Support for Resolutions, Indicating Stable Shareholder ConfidenceAGM/EGMmedium impact
Cruxal's analysis: EP Biocomposites Limited conducted its 7th AGM on September 28, 2026, with a total of 336…
Read the full analysis - Intimation of Strategic Collaboration and Consultancy Agreement entered with Malligavad Foundation and Anand MalligavadCompany Updatelow impact
- Closure of trading window till the publication of half yearly results of the CompanyInsider Trading / SASTlow impact
- EP Biocomposites Limited concludes 7th Annual General Meeting; adopts FY 2025-26 financial statementsAGM/EGMlow impact
Cruxal's analysis: EP Biocomposites Limited has successfully concluded its 7th Annual General Meeting held…
Read the full analysis - EP Biocomposites Limited secures INR 92.04 lakh order for Sewage Treatment PlantCompany Updatemedium impact
Cruxal's analysis: EP Biocomposites Limited has received a work order for the supply, installation, testing…
Read the full analysis - EP Biocomposites Limited Reports Record FY2025-26 Financials with Revenue of 13.64 Crore and Strategic R&D FocusAGM/EGMhigh impact
Cruxal's analysis: EP Biocomposites Limited has announced its strongest financial performance to date for…
Read the full analysis - EP Biocomposites Ltd releases investor presentation for upcoming Annual General MeetingCompany Updatelow impact
Cruxal's analysis: EP Biocomposites Ltd has filed its investor presentation ahead of the upcoming Annual…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.